Preliminary Third Quarter 2025 Results
Helped over 37,100 children in the third quarter 2025, the Company has now helped approximately 1.3 million children since inception
Generated preliminary unaudited third quarter 2025 net revenue of approximately $61.2 million, representing growth of 12% compared to $54.6 million in the third quarter of 2024. Preliminary domestic third quarter net revenue is expected to be approximately $48.7 million, representing 14% growth compared to the prior year period, and international net revenue is expected to be approximately $12.5 million, representing 6% growth compared to the prior year period, which was negatively impacted by the timing of set sales and large stocking orders in Latin and South America
Generated preliminary unaudited third quarter 2025 net revenue excluding 7D capital sales of approximately $60.7 million, representing growth of 17% compared to $51.8 million in the third quarter 2024. Preliminary domestic third quarter net revenue excluding 7D capital sales is expected to be approximately $48.2 million, representing growth of 19% compared to $40.5 million in the prior year period
The Company's updated 2025 guidance range reflects the uncertainty in timing of 7D capital sales and Latin and South America set sales and stocking orders
2025 Financial GuidanceFor the full year 2025, the Company now expects revenue of $233.5 million to $234.5 million, a decrease from the previous guidance range of $237.0 million to $242.0 million, representing growth of 14% to 15% over 2024 revenue. The Company reiterated its expectation for annual set deployment to be $15.0 million and reiterated the adjusted EBITDA guidance range of $15.0 million to $17.0 million for the full year of 2025.
"In the third quarter, we faced incremental headwinds late in September, largely driven by delayed 7D capital sales and headwinds within the Latin and South America segment of our business, which contributed to a revenue shortfall relative to our expectations. While still important parts of our business plan, order timing across these segments is difficult to forecast and will continue to be variable. We believe it is prudent to reflect minimal sales growth from these segments for the fourth quarter and into the future," commented David Bailey, President & CEO of OrthoPediatrics. "We are reaffirming a steadfast commitment to driving revenue growth that expands profitability and supports ...
